Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation

What Was Tested

Researchers studied Vasopressin and Desmopressin in this randomized controlled trial publication.

The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations.

Who Took Part

According to the abstract, 19 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Vasopressin.

A placebo (an inactive look-alike) gave the Vasopressin group a baseline to be compared against.

Groups ran in parallel: each of the patients stayed in one arm throughout.

What Was Measured

PubMed files the paper under topics including Coronary Artery Bypass, Deamino Arginine Vasopressin, Extracorporeal Circulation, Factor VIII, Hemostasis, Surgical, Platelet Aggregation and Randomized Controlled Trials as Topic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Circulation), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.